ModifiedUnitedHealthcarePolicy CS004ID.B

Therapeutic apheresis (plasmapheresis, photopheresis, apheresis modalities)

This policy governs coverage and medical necessity criteria for therapeutic apheresis procedures (including plasma exchange, photopheresis, LDL apheresis, immunoadsorption, and related modalities) for members in the state of Idaho, including Idaho Medicaid Plus plans.

Policy Summary

PayerUnitedHealthcare

PolicyTherapeutic apheresis (plasmapheresis, photopheresis, apheresis modalities)

Policy CodePolicy CS004ID.B

Change TypeDocumentation expectations addedreference link removed

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionEnsure the patient's medical record fully documents medical necessity (history, exam, and pertinent test results) and make records available for review.

SourceLink

POLICY UPDATE CHANGES

The patient's medical record must contain documentation that fully supports the medical necessity for the requested services.

Documentation includes but is not limited to relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures.

Documentation supporting the medical necessity should be legible, maintained in the patient's medical record, and must be made available upon request.

Removed reference link to the guidelines titled 'Medical Records Documentation Used for Reviews'.

IdahoState(s) this policy applies to

~60+Diagnoses/conditions listed

7 codesCPT codes listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Explicit documentation expectations listed

8-12 LHVP volume defined

Coverage and Medical Necessity Criteria

Vasculitis, Antineutrophil Cytoplasmic Antibody (ANCA)-Associated (AAV)

Vasculitis, ANCA-associated (AAV) — summary of evidence and coverage position

Plasma exchange (PLEX) is not associated with reductions in mortality, rates of complete remission, or overall adverse events in patients with ANCA-associated vasculitis (AAV) based on randomized controlled trial data (4 RCTs, n=827 comparing PLEX vs no PLEX; plus 1 RCT comparing PLEX vs pulse steroid).

Evidence summary and clinical application

Evidence considerations — potential early renal benefit

Although PLEX did not improve overall mortality or remission, subgroup and time‑limited analyses identified a potential early renal benefit: at 3 months PLEX was associated with a reduced incidence of end-stage renal disease (ESRD) compared with no PLEX (example: PE 1/43 vs no PE 10/41; RR 0.14; 95% CI 0.03–0.77) and compared with pulse steroid (RR 0.46; 95% CI 0.24–0.86).

This early renal benefit appears limited to short-term outcomes and has not translated into improved long-term survival or durable remission in the available RCT data. The evidence is insufficient to generalize a mortality or sustained remission advantage for PLEX in AAV.

Clinical decision making should individualize use of PLEX for AAV patients with rapidly progressive renal failure where short-term preservation of renal function is an important objective; clinicians should weigh the potential for early renal benefit against the lack of mortality benefit and the procedure risks.

Applicable Codes and Definitions

Applicable CPT Codes (reference list)CPT

0342T	Therapeutic apheresis with selective HDL delipidation and plasma reinfusion.
36511	Therapeutic apheresis; for white blood cells.
36512	Therapeutic apheresis; for red blood cells.
36513	Therapeutic apheresis; for platelets.
36514	Therapeutic apheresis; for plasma pheresis.
36516	Therapeutic apheresis; with extracorporeal immunoadsorption, selective adsorption or selective filtration and plasma reinfusion.
36522	Photopheresis, extracorporeal.

High-Volume Plasma Exchange (HVP) — volume definition

HVP volume definitionExchange of 15% of ideal body weight (representing ~8–12 L).

Plasma removal ratePlasma removed at 1–2 L per hour during the exchange.

Replacement fluidReplacement with plasma in equivalent volume to that removed.

Authorization, Documentation, and Operational Guidance

Billing Rule

Coding reference and prior authorization note

The following coding list is provided for reference only and inclusion does not imply coverage or guarantee reimbursement. Prior authorization requirements still apply per plan rules; inclusion here is to assist billing and prior authorization workflows.

Listing of codes is not all‑inclusive
Prior authorization decisions are determined by federal, state, and contractual requirements

Prior Authorization

Prior authorization: chronic RCE and ABO‑incompatible transplant

Requests for ongoing chronic automated red cell exchange (RCE) and procedures related to ABO‑incompatible transplantation (including intraoperative immunoadsorption or perioperative plasma exchange) generally require prior authorization. For chronic transfusion/RCE, provide treatment plan, frequency, monitoring plan, and documentation of benefit/risk assessment. For ABO‑incompatible transplant desensitization or intraoperative apheresis, submit transplant center protocol, crossmatch/HLA details, and expected perioperative immunomodulation.

Key Terms and Procedure Definitions

BACKGROUND — therapeutic apheresis modalities

Scope of therapeutic apheresisEncompasses extracorporeal procedures that remove or selectively remove blood components (plasmapheresis, photopheresis, LDL/LDL apheresis, immunoadsorption, leukocytapheresis, erythrocytapheresis).

Setting and durationUsually performed in an outpatient facility and typically requires several hours; some plasma exchange regimens may be performed daily for at least 1 week.

General mechanismBlood is processed extracorporeally to separate and remove targeted components with reinfusion of remaining components plus appropriate replacement fluids.

High-Volume Plasma Exchange (HVP)

DefinitionHigh-Volume Plasma Exchange (HVP) is defined as an exchange of 15% of ideal body weight (representing ~8–12 L).

Removal rate

Recommended Line of Therapy and Treatment Sequencing

inv-69: mixed

Mixed line‑of‑therapy guidance: Policy distinguishes first‑line and second‑line use for multiple indications (eg, cryoglobulinemia second‑line; graft‑versus‑host chronic second‑line; focal segmental glomerulosclerosis recurrent in transplant second‑line).

Refer to indication‑specific entries for line‑of‑therapy assignment and required documentation.

inv-70: second-line

Second‑line/adjunctive uses: TPE/plasmapheresis is often used as a second‑line or adjunctive therapy in multiple myeloma with AKI/cast nephropathy (in combination with chemotherapy) and for other disorders where ASFA assigns Category II or where evidence supports use after failure of standard therapy.

Prior authorization should document prior/concurrent chemotherapy and intent to use TPE as adjunctive therapy.

inv-71: palliative

Laboratory and Biomarker Documentation Requirements

Serum Free Light Chains (FLC) — biomarker requirement

FLC biomarker roleSerum free light chains (FLC) are required for patient selection and monitoring when considering TPE as adjunctive therapy for multiple myeloma with cast nephropathy.

Documentation requirementAuthorization for TPE in myeloma-associated AKI should include baseline FLC levels and trends to support clinical necessity.

Interpretation noteReduction in FLCs with plasmapheresis is reported in retrospective studies; survival benefit independent of chemotherapy is not consistently demonstrated.

Treatment Regimens and Protocols

Regimen	Typical Components / Schedule	Indication / Rationale	Coverage stance
Plasmapheresis combined with low‑dose IVIG
Serial plasmapheresis sessions performed in the days immediately before transplantation, followed by low‑dose IVIG (dose and timing per protocol)
Desensitization for HLA‑sensitized kidney transplant candidates to reduce donor‑specific antibody and convert positive crossmatch to negative; used when transplant planned imminently

Regimen	Typical Components / Schedule	Evidence note	Coverage stance
Plasmapheresis alone for extracorporeal removal of serum free light chains (sFLC)
Multiple plasmapheresis sessions (variable; often 2–3 sessions reported) without concomitant chemotherapy used to lower sFLC levels
Extracorporeal removal of sFLCs via plasmapheresis reduces circulating free light chain levels but systematic review/meta-analysis shows no consistent survival benefit independent of chemotherapy; benefit is unclear without concurrent chemotherapy

Regimen	Typical Components / Schedule	Evidence note	Coverage stance
Multiple sessions (often ≥3) of therapeutic plasma exchange (TPE) combined with standard chemotherapy (eg, bortezomib‑based regimens)
Repeated daily or alternate‑day TPE sessions (commonly ≥3) administered alongside chemotherapy (bortezomib and other anti‑myeloma agents); replacement fluid per standard plasma exchange practice
Retrospective single‑center series and a meta‑analysis of RCTs report greater reduction in free light chains and lower dialysis‑dependence rates when plasmapheresis/TPE is used adjunctively with chemotherapy; pooled analyses show reduced dialysis dependence (eg, 15.6% vs 37.2%) though survival benefit is inconsistent

Clinical Background and Evidence Overview

Therapeutic apheresis comprises multiple extracorporeal modalities including plasma exchange/plasmapheresis, extracorporeal photopheresis (ECP), immunoadsorption, leukocytapheresis/granulocytapheresis, and erythrocytapheresis/red blood cell exchange. Procedures remove targeted plasma components, cells, or immunoglobulins and are typically outpatient interventions that may require several hours per session; in some clinical contexts, exchanges may be performed daily for at least one week. High‑volume plasma exchange is defined elsewhere in this policy as an exchange of approximately 15% of ideal body weight (about 8–12 L) with typical removal rates of 1–2 L per hour.

Policy Summary

PayerUnitedHealthcare

PolicyTherapeutic apheresis (plasmapheresis, photopheresis, apheresis modalities)

Policy CodePolicy CS004ID.B

Change TypeDocumentation expectations addedreference link removed

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionEnsure the patient's medical record fully documents medical necessity (history, exam, and pertinent test results) and make records available for review.

SourceLink

On This Page

Include procedural frequency and duration for chronic RCE
For transplant-related apheresis include transplant center plan and anticipated postoperative monitoring

Prior Authorization

Prior authorization guided by ASFA categories

Prior authorization determinations will be informed by the ASFA category and grade for the requested indication. Requests for Category I or II indications with supporting guideline evidence are more likely to be approved; Category III requests require individualized justification; Category IV requests may require IRB approval and are subject to non‑coverage.

Specify ASFA category and recommendation grade in the request
For Category IV indications indicate IRB approval if available

Prior Authorization

Guideline‑driven prior authorization

Prior authorization will align with specialty society guidance (e.g., ASFA, AAN, NCCN, NICE, ASH). Requests should document that guideline‑preferred therapies and recommended sequencing were considered and why apheresis is indicated (e.g., plasmapheresis for hyperviscosity, TPE adjunctive to chemotherapy for myeloma cast nephropathy when appropriate).

State which guideline(s) were consulted and how the patient meets guideline criteria
If apheresis is requested as second‑line, document prior therapies and response

Denial Risk

Lack of medical record documentation support may affect authorization

Incomplete, illegible, or missing medical record documentation may result in delays, requests for additional information, or denial of the request. Maintain complete, legible records and make them available upon request for utilization review and audits.

Lack of documentation may trigger denial or require submission of additional records
Ensure records are legible and retained in the patient's medical record

Prior Authorization

HTG‑AP outcome uncertainty — require justification

Systematic reviews and meta‑analyses for hypertriglyceridemia‑induced acute pancreatitis (HTG‑AP) show faster triglyceride reduction with plasmapheresis but an observed higher in‑hospital mortality in plasmapheresis groups in observational studies; confounding limits interpretation. Prior authorization should reflect the uncertain impact on clinical outcomes and request rationale and alternative therapies attempted.

Document why plasmapheresis is preferred over conventional therapy in this case
Provide severity indicators and timing relative to symptom onset

Note

Device regulatory / indication consideration

Device regulatory status may be considered in coverage decisions. FDA approval or device PMA status is informational and not by itself a basis for coverage; however, indicate when an FDA‑approved system (e.g., Therakos CELLEX/UVAR XTS for ECP in CTCL) will be used.

Include device name and model when relevant to the request
Note that filtration devices (Class III) and centrifugal devices (Class II/III) have differing regulatory pathways

Denial Risk

Documentation‑related denial risk

Missing required documentation elements (history, exam, diagnostic test results, prior therapy details, treatment plan) may lead to denial or non‑approval. Provide all requested records promptly to avoid adverse coverage determinations.

Failure to provide documentation upon request may result in denial
Keep complete records to support medical necessity

Documentation Required

Medical record documentation required for reviews

The patient's medical record must contain documentation that fully supports medical necessity for the requested apheresis procedure. Required elements include relevant medical history, physical examination, laboratory and imaging results, details of prior therapies and response, and the planned apheresis modality, frequency, and duration.

History and physical examination findings supportive of the indication
Pertinent diagnostic test results (e.g., antibody titers, LDL‑C, triglycerides, FLC levels)
Prior therapies tried, dates, response, and rationale for escalation to apheresis
Planned apheresis details: type (TPE, immunoadsorption, RCE, LA, ECP), replacement fluid, frequency, estimated number of sessions, and monitoring plan
For transplant/desensitization include HLA/DSA/crossmatch data and transplant timing

Note

Supporting evidence citation

When applicable, cite supporting clinical evidence or trials in the authorization request (e.g., meta‑analyses or RCTs supporting use in ANCA‑associated vasculitis for short‑term renal protection, or observational data for lipoprotein apheresis in homozygous FH). This facilitates timely review.

Reference relevant RCTs, meta‑analyses, or high‑quality observational studies
Attach or summarize key outcome measures and applicability to the patient

Documentation Required

Document prior therapy and inflammatory marker trend

Document prior therapies and trends in relevant inflammatory or disease markers (e.g., CRP, WBC, triglycerides, LDL‑C, free light chains, antibody titers) to show treatment effect or progression and to justify initiation or continuation of apheresis.

Include baseline and serial marker values with dates
Describe temporal relationship between marker trends and prior treatments

Documentation Required

Clinical indication documentation

Clearly document how the clinical indication aligns with society guidance. Provide indication‑specific detail (for example: hyperviscosity with symptomatic visual/neurologic impairment; familial hypercholesterolemia with genetic confirmation and LDL‑C values despite maximal therapy; myeloma cast nephropathy with AKI and high free light chains).

State the precise clinical indication and correlate to guideline language
For FH include genetic testing results and maximal tolerated lipid therapy history

Step Therapy

Line / step therapy distinctions

Distinguish whether the requested apheresis is intended as first‑line vs second‑line therapy. Where the policy or guideline specifies sequencing (first‑line vs second‑line), document prior use of recommended first‑line therapies and the clinical rationale for deviation.

State if this is first‑line or second‑line for the specific diagnosis
If second‑line, list prior therapies, durations, and objective evidence of failure or intolerance

Prior Authorization

KPD before desensitization

For sensitized kidney transplant candidates, consider kidney‑paired donation (KPD) before desensitization when feasible. If desensitization is pursued instead, document why KPD was not suitable or was unavailable, referencing donor/recipient phenotype and antibody strength.

Document KPD evaluation and outcomes or reasons KPD was not an option
If desensitization chosen, include donor‑specific antibody strength and intended peri‑transplant plan

Step Therapy

Step therapy not defined — provide clinical rationale

This policy does not define explicit step therapy algorithms for all indications. Prior authorization reviewers will apply guideline recommendations and individualized clinical judgment; when step therapy is relevant, provide documentation of prior steps taken.

If prior authorization relies on a step, describe completed steps and dates
Absence of a defined step therapy algorithm requires clearer clinical justification for non‑standard sequencing

Prior Authorization

Sequence of therapies per guideline

When society guidelines specify therapy sequencing (for example, AAN and ASFA recommendations for neurologic indications or NICE recommendations for FH), include documentation that preferred first‑line options were considered and reasons for selecting apheresis at the requested point in the sequence.

Explain sequencing considered and why apheresis is indicated now
For neurologic indications document timing relative to symptom onset and prior immunotherapies

Step Therapy

Lipid apheresis step therapy

For lipoprotein apheresis requests (familial hypercholesterolemia), document trials of maximal tolerated lipid‑modifying drug therapy and explain why medical therapy was insufficient. For pediatric patients, indicate that lipid‑modifying drug therapy was considered before LDL apheresis per NICE when applicable.

Provide LDL‑C values on and off therapy, genetic confirmation when available
Document duration and intensity of prior lipid‑lowering therapy

Patient plasma is removed at a rate of 1–2 L per hour during HVP.

ReplacementRemoved plasma is replaced with plasma in equivalent volume.

Extracorporeal Photopheresis (ECP)

Procedure descriptionExtracorporeal photopheresis (ECP) separates the buffy coat, treats collected leukocytes extracorporeally with a photoactive compound (e.g., psoralens), exposes them to UVA light, and reinfuses them during the same procedure.

Therapeutic intentAn immunomodulatory apheresis-based therapy used for disorders such as cutaneous T‑cell lymphoma and other immune-mediated conditions in some settings.

Typical workflowCollection of buffy coat, extracorporeal photoactivation, then reinfusion in a single session.

Immunoadsorption (IA)

TechniqueImmunoadsorption (IA) involves passing separated plasma through a device that specifically binds and removes immunoglobulins (e.g., Staphylococcal protein A).

TargetSelective removal of pathogenic antibodies or immunoglobulin fractions from patient plasma.

Use caseOften employed for antibody‑mediated conditions or as part of desensitization protocols in transplant settings.

Desensitization (kidney transplant)

DefinitionDesensitization protocols use plasmapheresis with low‑ or high‑dose IVIG and/or immunoadsorption to reduce anti‑HLA antibodies and convert positive crossmatches to negative prior to transplantation.

Timing considerationPlasmapheresis does not produce durable HLA antibody reduction unless transplantation occurs within several days after the last treatment.

Patient selectionTargeted to highly sensitized patients (eg, PRA >50% or strong donor‑specific antibodies) to enable live‑donor or deceased‑donor transplantation when matched donor otherwise unavailable.

Lipoprotein apheresis (LA)

DefinitionLipoprotein apheresis (LA) is repeated extracorporeal removal of lipoproteins to lower LDL‑C and lipoprotein(a).

Typical indicationsUsed in genetically confirmed homozygous familial hypercholesterolemia (hoFH) and selected refractory heterozygous FH or markedly elevated Lp(a) despite maximal medical therapy.

Treatment frequencyFrequency ranges from twice weekly to once every three weeks; more frequent (eg, weekly or twice weekly) treatments achieve greater LDL‑C reductions.

PLEX — definition and context

DefinitionPLEX (plasma exchange) refers to extracorporeal removal of plasma with replacement and is used as second‑line or adjunctive therapy in conditions such as acute optic neuritis in NMO/NMOSD.

Context of useEmployed as second‑line/adjunctive therapy when first‑line treatments fail or in severe relapses, with variable evidence of benefit in NMOSD optic neuritis.

Evidence noteAvailable observational data are limited and inconsistent; controlled trials are lacking to definitively establish efficacy for some indications.

ABO-IA (intraoperative immunoadsorption)

DefinitionABO‑IA denotes intraoperative anti‑A/B immunoadsorption used to reduce isohemagglutinins and facilitate ABO‑incompatible transplantation.

Comparative outcomesIn pediatric series, ABO‑IA was associated with lower blood product transfusion volumes and comparable rejection and survival rates versus plasma exchange (ABO‑PE).

ApplicationUsed intraoperatively to permit ABO‑incompatible heart transplantation in older pediatric recipients and reduce transfusion needs.

RCE / aRBX — automated red cell exchange

DefinitionAutomated red cell exchange (RCE / aRBX) is an apheresis procedure that removes patient red blood cells and replaces them with donor RBCs to lower HbS fraction.

IndicationsUsed in sickle cell disease for acute complications (eg, acute chest syndrome, stroke) and chronic transfusion programs to manage HbS and limit iron accumulation.

Safety and outcomesPediatric chronic RCE cohorts report adverse event rates (eg, hypocalcemia most common); observational data suggest lower alloimmunization rates with ECP/RCE compared with simple transfusion.

ASFA categories — I–IV summary

ASFA Category IDisorders for which apheresis is accepted as first‑line therapy (primary standalone or with other treatments).

ASFA Category IIDisorders for which apheresis is accepted as second‑line therapy (standalone or with other treatments).

ASFA Category III and IVCategory III: role not established (individualized decision making). Category IV: evidence suggests apheresis is ineffective or harmful; IRB oversight desirable if undertaken.

Red blood cell (RBC) exchange

DefinitionRed blood cell (RBC) exchange is an automated apheresis procedure removing sickled HbS‑containing RBCs and replacing them with donor RBCs.

Key indicationsIndicated for acute stroke, severe acute chest syndrome, and primary/secondary stroke prophylaxis in sickle cell disease per society guidance.

BenefitAutomated RBC exchange is more efficient at removing HbS and reduces transfusional iron accumulation compared to simple transfusion.

Extracorporeal photopheresis (ECP) — device/regulatory note

Device/regulatory noteECP devices are regulated by FDA; one PMA‑approved system (Therakos CELLEX/UVAR XTS with UVADEX) is approved for palliative treatment of CTCL skin manifestations unresponsive to other treatments.

Procedure natureECP is an apheresis‑based immunomodulatory therapy involving extracorporeal photoactivation of collected leukocytes with reinfusion.

Coverage implicationFDA device approval is informational; coverage decisions should consider indication‑specific evidence strength and guideline recommendations.

Therapeutic apheresis — modalities referenced

Modalities referencedModalities include plasma exchange/plasmapheresis, extracorporeal photopheresis, LDL/LDL apheresis, immunoadsorption, leukocytapheresis/granulocytapheresis, erythrocytapheresis/red cell exchange, and selective filtration techniques.

Typical clinical rolesUsed to remove pathogenic plasma components, cells, or immunoglobulins across a range of hematologic, neurologic, renal, cardiologic, and transplant indications.

Procedure logisticsMost procedures are outpatient, require several hours, and may be repeated or performed daily in select clinical situations.

Palliative use: Extracorporeal photopheresis (ECP) is an FDA‑approved palliative option for CTCL skin manifestations unresponsive to other treatments; other apheresis modalities may be used palliatively per disease‑specific guideline statements and clinical judgment.

Document palliative intent and prior therapies; device regulatory status may inform coverage.